InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer
October 4, 2021

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk assessment tests and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer and disease cases. According to the announcements, those cases include 22 identified types of cancer, 25 identified types of precancer and multiple other related diseases. The company also noted that based on an initial analysis, the confirmed cases strongly correlate to CDA test scores. These results confirm that AnPac’s CDA test provides an effective method to initially screen for risks associated with cancer. “We are very pleased to reach the milestone of confirming over 2,000 cases and to achieve significant validation of CDA technology for general population cancer and pre-cancer risk assessment,” said AnPac Bio CEO and chair Dr. Chris Yu in the press release. “This is truly a breakthrough technology in catching multiple cancer and pre-cancer types earlier to prevent cancer and provide better patient outcomes. We are very proud of our contributions to the battle against cancer and we are contributing to save lives now. We are already making a significant impact in the fight against cancer through our innovative ideas (multi-cancer detection), technology development and finding potential cancer and pre-cancer earlier on a daily basis. We believe our CDA technology’s results speak for themselves and expect that public health agencies and organizations seeking the most promising tools for detecting cancer and pre-cancer earlier will look closely at AnPac Bio.”

To view the full press release, visit https://ibn.fm/FAvE5

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 148 issued patents as of June 30, 2021. With one CLIA and CAP registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation, early cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).